首页 > 最新文献

Journal of geriatric oncology最新文献

英文 中文
Managing older patients with oral targeted cancer therapies in primary care: A qualitative study 在初级保健中管理使用口服癌症靶向疗法的老年患者:定性研究。
IF 3 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.jgo.2024.101843
Murielle Glondu-Lassis , Béatrice Lognos , Michel Amouyal , François Carbonnel , Bernard Clary , Valéry Antoine
{"title":"Managing older patients with oral targeted cancer therapies in primary care: A qualitative study","authors":"Murielle Glondu-Lassis , Béatrice Lognos , Michel Amouyal , François Carbonnel , Bernard Clary , Valéry Antoine","doi":"10.1016/j.jgo.2024.101843","DOIUrl":"10.1016/j.jgo.2024.101843","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"15 8","pages":"Article 101843"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141912963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The applicability of the Cancer and Aging Research Group (CARG) chemotherapy toxicity prediction tool 癌症与衰老研究小组(CARG)化疗毒性预测工具的适用性。
IF 3 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.jgo.2024.102070
Neha Pathak , Tomohiro F. Nishijima , Eyyüp Cavdar
{"title":"The applicability of the Cancer and Aging Research Group (CARG) chemotherapy toxicity prediction tool","authors":"Neha Pathak , Tomohiro F. Nishijima , Eyyüp Cavdar","doi":"10.1016/j.jgo.2024.102070","DOIUrl":"10.1016/j.jgo.2024.102070","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"15 8","pages":"Article 102070"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142289105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of Glasgow Prognostic Score with frailty, mortality and adverse health outcomes in older patients with cancer: A prospective cohort study 格拉斯哥预后评分与老年癌症患者的虚弱程度、死亡率和不良健康后果的关系:前瞻性队列研究。
IF 3 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.jgo.2024.102075
Yara van Holstein , Stella Trompet , Barbara C. van Munster , P. Janne E. van den Berkmortel , Diana van Heemst , Nienke A. de Glas , Marije Slingerland , P. Eline Slagboom , Cynthia Holterhues , Geert Labots , Simon P. Mooijaart , Johanneke E.A. Portielje , Frederiek van den Bos

Introduction

To balance benefits and risks of cancer treatment in older patients, prognostic information is needed. The Glasgow Prognostic Score (GPS), composed of albumin and C-reactive protein (CRP), might provide such information. This study first aims to investigate the association between GPS and frailty, functional decline, and health-related quality of life (HRQoL) decline as indicators of health problems in older patients with cancer. The second aim is to study the predictive value of GPS for mortality, in addition to clinical predictors.

Materials and Methods

This prospective cohort study included patients aged ≥70 years with a solid malignant tumor who underwent a geriatric assessment and blood sampling before treatment initiation. GPS was calculated using serum albumin and CRP measured in batch, categorized into normal (0) and abnormal GPS (1–2). Outcomes were all-cause mortality and a composite outcome of decline in daily functioning and/or HRQoL, or mortality at one year follow-up. Daily functioning was assessed by Activities of Daily Living and Instrumental Activities of Daily Living questionnaires and HRQoL by the EQ-5D-3L and EQ-VAS questionnaires.

Results

In total, 192 patients with a median age of 77 years (interquartile range 72.3–81.0) were included. Patients with abnormal GPS were more often frail compared to those with normal GPS (79 % vs. 63 %, p = 0.03). Patients with abnormal GPS had higher mortality rates after one year compared to those with normal GPS (48 % vs. 23 %, p < 0.01) in unadjusted analysis. Abnormal GPS was associated with increased mortality risk (hazard ratio 2.8, 95 % CI 1.7–4.8). The area under the receiver operating characteristics curve of age, distant metastasis, tumor site, comorbidity, and malnutrition combined was 0.73 (0.68–0.83) for mortality prediction, and changed to 0.78 (0.73–0.86) with GPS (p = 0.10). The composite outcome occurred in 88 % of patients with abnormal GPS versus 83 % with normal GPS (p = 0.44).

Discussion

Abnormal GPS was associated with frailty and mortality. The addition of GPS to clinical predictors showed a numerically superior mortality prediction in this cohort of older patients with cancer, although not statistically significant. While GPS may improve the stratification of future older patients with cancer, larger studies including older patients with similar tumor types are necessary to evaluate its clinical usefulness.

Trial Registration

The TENT study is retrospectively registered at the Netherlands Trial Register (NTR), trial number NL8107. Date of registration: 22-10-2019.
介绍:为了平衡老年患者接受癌症治疗的益处和风险,需要预后信息。由白蛋白和 C 反应蛋白(CRP)组成的格拉斯哥预后评分(GPS)可提供此类信息。本研究的第一个目的是调查作为老年癌症患者健康问题指标的全球定位系统与虚弱、功能衰退和健康相关生活质量(HRQoL)下降之间的关联。第二个目的是研究除临床预测因素外,GPS 对死亡率的预测价值:这项前瞻性队列研究纳入了年龄≥70岁的实体恶性肿瘤患者,他们在开始治疗前接受了老年病学评估和血液采样。利用分批测量的血清白蛋白和 CRP 计算 GPS,分为正常 GPS(0)和异常 GPS(1-2)。随访结果为全因死亡率、日常功能和/或 HRQoL 下降的综合结果或随访一年后的死亡率。日常功能通过日常生活活动和工具性日常生活活动问卷进行评估,HRQoL通过EQ-5D-3L和EQ-VAS问卷进行评估:共纳入192名患者,中位年龄为77岁(四分位数间距为72.3-81.0)。与全球定位系统正常的患者相比,全球定位系统异常的患者更加虚弱(79% 对 63%,P = 0.03)。与全球定位系统正常的患者相比,全球定位系统异常的患者一年后的死亡率更高(48% 对 23%,P 讨论):GPS异常与虚弱和死亡率有关。在这组老年癌症患者中,将 GPS 添加到临床预测指标中后,对死亡率的预测在数量上更胜一筹,但在统计学上并不显著。虽然全球定位系统可能会改善未来老年癌症患者的分层,但仍有必要进行更大规模的研究,包括具有类似肿瘤类型的老年患者,以评估其临床实用性:TENT研究在荷兰试验注册中心(NTR)进行了回顾性注册,试验编号为NL8107。注册日期:2019年10月22日。
{"title":"Association of Glasgow Prognostic Score with frailty, mortality and adverse health outcomes in older patients with cancer: A prospective cohort study","authors":"Yara van Holstein ,&nbsp;Stella Trompet ,&nbsp;Barbara C. van Munster ,&nbsp;P. Janne E. van den Berkmortel ,&nbsp;Diana van Heemst ,&nbsp;Nienke A. de Glas ,&nbsp;Marije Slingerland ,&nbsp;P. Eline Slagboom ,&nbsp;Cynthia Holterhues ,&nbsp;Geert Labots ,&nbsp;Simon P. Mooijaart ,&nbsp;Johanneke E.A. Portielje ,&nbsp;Frederiek van den Bos","doi":"10.1016/j.jgo.2024.102075","DOIUrl":"10.1016/j.jgo.2024.102075","url":null,"abstract":"<div><h3>Introduction</h3><div>To balance benefits and risks of cancer treatment in older patients, prognostic information is needed. The Glasgow Prognostic Score (GPS), composed of albumin and C-reactive protein (CRP), might provide such information. This study first aims to investigate the association between GPS and frailty, functional decline, and health-related quality of life (HRQoL) decline as indicators of health problems in older patients with cancer. The second aim is to study the predictive value of GPS for mortality, in addition to clinical predictors.</div></div><div><h3>Materials and Methods</h3><div>This prospective cohort study included patients aged ≥70 years with a solid malignant tumor who underwent a geriatric assessment and blood sampling before treatment initiation. GPS was calculated using serum albumin and CRP measured in batch, categorized into normal (0) and abnormal GPS (1–2). Outcomes were all-cause mortality and a composite outcome of decline in daily functioning and/or HRQoL, or mortality at one year follow-up. Daily functioning was assessed by Activities of Daily Living and Instrumental Activities of Daily Living questionnaires and HRQoL by the EQ-5D-3L and EQ-VAS questionnaires.</div></div><div><h3>Results</h3><div>In total, 192 patients with a median age of 77 years (interquartile range 72.3–81.0) were included. Patients with abnormal GPS were more often frail compared to those with normal GPS (79 % vs. 63 %, <em>p</em> = 0.03). Patients with abnormal GPS had higher mortality rates after one year compared to those with normal GPS (48 % vs. 23 %, <em>p</em> &lt; 0.01) in unadjusted analysis. Abnormal GPS was associated with increased mortality risk (hazard ratio 2.8, 95 % CI 1.7–4.8). The area under the receiver operating characteristics curve of age, distant metastasis, tumor site, comorbidity, and malnutrition combined was 0.73 (0.68–0.83) for mortality prediction, and changed to 0.78 (0.73–0.86) with GPS (<em>p</em> = 0.10). The composite outcome occurred in 88 % of patients with abnormal GPS versus 83 % with normal GPS (<em>p</em> = 0.44).</div></div><div><h3>Discussion</h3><div>Abnormal GPS was associated with frailty and mortality. The addition of GPS to clinical predictors showed a numerically superior mortality prediction in this cohort of older patients with cancer, although not statistically significant. While GPS may improve the stratification of future older patients with cancer, larger studies including older patients with similar tumor types are necessary to evaluate its clinical usefulness.</div></div><div><h3>Trial Registration</h3><div>The TENT study is retrospectively registered at the Netherlands Trial Register (NTR), trial number NL8107. Date of registration: 22-10-2019.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"15 8","pages":"Article 102075"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142467437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predicting short-term treatment toxicity in head and neck cancer through a systematic review and meta-analysis 通过系统综述和荟萃分析预测头颈癌的短期治疗毒性。
IF 3 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.jgo.2024.102064
Marco A. Mascarella , Varun Vendra , Khalil Sultanem , Christina Tsien , George Shenouda , Shaum Sridharan , Nathaniel Bouganim , Khashayar Esfahani , Keith Richardson , Alex Mlynarek , Michael Hier , Nader Sadeghi , Umamaheswar Duvvuri , Marie-Jeanne Kergoat

Introduction

Frailty is a recognized condition associated with poorer outcomes in patients with head and neck cancer (HNC). The objective of this study was to ascertain the prognostic significance of various frailty metrics on short-term treatment toxicity in patients with HNC undergoing curative-intent therapy.

Materials and Methods

A systematic review was performed searching multiple databases. An inverse-variation, random-effects model was used to perform the meta-analysis to evaluate the prognostic significance of various frailty metrics on short-term treatment-related toxicity in this population.

Results

A total of 292,560 patients with HNC originating from 36 observational studies were analyzed. The most frequently reported frailty metrics were the modified frailty index (mFI), Geriatric 8 questionnaire (G8), Adjusted Clinical Groups (ACG), Groningen Frailty Indicator (GFI), and comprehensive geriatric assessment (CGA). The overall prevalence of frailty using any metric in all included studies was 7.5 %. The combined odds ratio (OR) for short-term treatment toxicity using the mFI was 2.60 (95 % CI of 1.81–3.72), G8 2.69 (95 % CI 1.37–5.28), ACG 3.43 (95 %CI 2.52–4.67), GFI 2.71 (95 % CI 1.11–6.62), and CGA 3.36 (95 % CI 1.18–9.53). The association of frailty with short-term treatment toxicity using various frailty metrics was more pronounced in patients with upfront surgery (OR 3.00, 95 %CI of 2.35–3.81) compared to definitive (chemo)radiotherapy 2.64 (95 % CI 1.04–6.68).

Discussion

Various frailty metrics exists in the HNC literature, with the most common being the mFI, G8, ACG, GFI, and CGA. Patients with HNC and frailty are more than twice as likely to suffer a short-term treatment-related toxicity when undergoing curative-intent HNC treatment than patients without frailty. This effect is more pronounced in patients undergoing upfront surgery.
导言:体弱是头颈癌(HNC)患者预后较差的一个公认因素。本研究旨在确定各种虚弱指标对接受根治性治疗的 HNC 患者短期治疗毒性的预后意义:对多个数据库进行了系统性检索。采用反变异随机效应模型进行荟萃分析,评估各种虚弱指标对该人群短期治疗相关毒性的预后意义:共分析了来自36项观察性研究的292 560名HNC患者。最常报告的虚弱指标包括改良虚弱指数(mFI)、老年医学 8 问卷(G8)、调整临床组(ACG)、格罗宁根虚弱指标(GFI)和老年医学综合评估(CGA)。在所有纳入的研究中,采用任何指标的虚弱总体发生率为 7.5%。使用 mFI 得出的短期治疗毒性综合几率比 (OR) 为 2.60(95 % CI 为 1.81-3.72),G8 为 2.69(95 % CI 为 1.37-5.28),ACG 为 3.43(95 % CI 为 2.52-4.67),GFI 为 2.71(95 % CI 为 1.11-6.62),CGA 为 3.36(95 % CI 为 1.18-9.53)。与确定性(化疗)放疗相比,前期手术(OR 3.00,95 %CI 为 2.35-3.81)患者的虚弱程度与短期治疗毒性的关系更为明显,而采用各种虚弱程度指标的患者的虚弱程度与短期治疗毒性的关系为 2.64 (95 % CI 1.04-6.68):HNC文献中有各种虚弱指标,其中最常见的是mFI、G8、ACG、GFI和CGA。HNC合并体弱的患者在接受治愈性HNC治疗时,出现短期治疗相关毒性反应的几率是非体弱患者的两倍多。这种影响在接受前期手术的患者中更为明显。
{"title":"Predicting short-term treatment toxicity in head and neck cancer through a systematic review and meta-analysis","authors":"Marco A. Mascarella ,&nbsp;Varun Vendra ,&nbsp;Khalil Sultanem ,&nbsp;Christina Tsien ,&nbsp;George Shenouda ,&nbsp;Shaum Sridharan ,&nbsp;Nathaniel Bouganim ,&nbsp;Khashayar Esfahani ,&nbsp;Keith Richardson ,&nbsp;Alex Mlynarek ,&nbsp;Michael Hier ,&nbsp;Nader Sadeghi ,&nbsp;Umamaheswar Duvvuri ,&nbsp;Marie-Jeanne Kergoat","doi":"10.1016/j.jgo.2024.102064","DOIUrl":"10.1016/j.jgo.2024.102064","url":null,"abstract":"<div><h3>Introduction</h3><div>Frailty is a recognized condition associated with poorer outcomes in patients with head and neck cancer (HNC). The objective of this study was to ascertain the prognostic significance of various frailty metrics on short-term treatment toxicity in patients with HNC undergoing curative-intent therapy.</div></div><div><h3>Materials and Methods</h3><div>A systematic review was performed searching multiple databases. An inverse-variation, random-effects model was used to perform the meta-analysis to evaluate the prognostic significance of various frailty metrics on short-term treatment-related toxicity in this population.</div></div><div><h3>Results</h3><div>A total of 292,560 patients with HNC originating from 36 observational studies were analyzed. The most frequently reported frailty metrics were the modified frailty index (mFI), Geriatric 8 questionnaire (G8), Adjusted Clinical Groups (ACG), Groningen Frailty Indicator (GFI), and comprehensive geriatric assessment (CGA). The overall prevalence of frailty using any metric in all included studies was 7.5 %. The combined odds ratio (OR) for short-term treatment toxicity using the mFI was 2.60 (95 % CI of 1.81–3.72), G8 2.69 (95 % CI 1.37–5.28), ACG 3.43 (95 %CI 2.52–4.67), GFI 2.71 (95 % CI 1.11–6.62), and CGA 3.36 (95 % CI 1.18–9.53). The association of frailty with short-term treatment toxicity using various frailty metrics was more pronounced in patients with upfront surgery (OR 3.00, 95 %CI of 2.35–3.81) compared to definitive (chemo)radiotherapy 2.64 (95 % CI 1.04–6.68).</div></div><div><h3>Discussion</h3><div>Various frailty metrics exists in the HNC literature, with the most common being the mFI, G8, ACG, GFI, and CGA. Patients with HNC and frailty are more than twice as likely to suffer a short-term treatment-related toxicity when undergoing curative-intent HNC treatment than patients without frailty. This effect is more pronounced in patients undergoing upfront surgery.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"15 8","pages":"Article 102064"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142289104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Age and postoperative swallowing function in patients treated for advanced oral cancer: A retrospective study 晚期口腔癌患者的年龄与术后吞咽功能:回顾性研究
IF 3 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.jgo.2024.101841
Seth E. Amos , Georges E. Daoud , Shubham R. Patel , Andre J. Burnham , Lauren Ottenstein , H. Michael Baddour , Andrew Tkaczuk , Nicole C. Schmitt
{"title":"Age and postoperative swallowing function in patients treated for advanced oral cancer: A retrospective study","authors":"Seth E. Amos ,&nbsp;Georges E. Daoud ,&nbsp;Shubham R. Patel ,&nbsp;Andre J. Burnham ,&nbsp;Lauren Ottenstein ,&nbsp;H. Michael Baddour ,&nbsp;Andrew Tkaczuk ,&nbsp;Nicole C. Schmitt","doi":"10.1016/j.jgo.2024.101841","DOIUrl":"10.1016/j.jgo.2024.101841","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"15 8","pages":"Article 101841"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141878838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trends in the use of granulocyte colony stimulating factors for older patients with cancer, 2010 to 2019 2010 年至 2019 年老年癌症患者使用粒细胞集落刺激因子的趋势。
IF 3 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.jgo.2024.102049
Kaylee Fish , Daoqi Gao , Mukaila Raji , Lodovico Balducci , Yong-Fang Kuo

Introduction

Older patients with cancer receiving myelosuppressive treatment are at an increased risk for developing febrile neutropenia (FN) or having chemotherapy dose-reductions or delays, resulting in suboptimal health outcomes. Granulocyte colony stimulating factors (G-CSF) are effective medications to reduce these adverse events and are recommended for patients 65 years receiving chemotherapy with >10 % FN risk. We sought to characterize the trends and predictors of G-CSF use between the youngest-old (66–74 years), middle-old (75–84 years), and oldest-old (85 years) patients with cancer.

Materials and Methods

We used registry data from SEER-Medicare for breast, lung, ovarian, colorectal, esophageal, gastric, uterine, prostate, pancreatic cancer, and non-Hodgkin lymphoma (NHL) diagnoses from 2010 to 2019. Cox proportional hazard analysis was used.

Results

Overall, 41.4 % of patients received G-CSF from chemotherapy initiation to three days after completion of the first chemotherapy course. The use rate remained relatively stable for all cancers, except for an increase in use for those with pancreatic cancer. G-CSF use decreased as patients got older. The oldest-old were 43.0 % (95 % confidence interval: 40.7–45.2 %) less likely to receive G-CSF compared to the youngest-old. Patients with breast cancer or NHL were more likely to receive G-CSF than those with other cancers. Patients who were female, married, White or Hispanic, and had fewer comorbidities were more likely to receive G-CSF.

Discussion

G-CSF is used less often in populations at higher risk of developing FN and related complications. Improving adherence to recommendations can improve health outcomes, especially in the oldest adults, older males, and Black patients.
简介接受骨髓抑制治疗的老年癌症患者发生发热性中性粒细胞减少症(FN)或化疗剂量减少或延迟的风险增加,从而导致不理想的健康状况。粒细胞集落刺激因子(G-CSF)是减少这些不良事件的有效药物,建议年龄≥65 岁、接受化疗且 FN 风险大于 10% 的患者使用。我们试图描述最年轻(66-74 岁)、中等年龄(75-84 岁)和最年长(≥85 岁)癌症患者使用 G-CSF 的趋势和预测因素:我们使用了SEER-Medicare的登记数据,包括2010年至2019年诊断的乳腺癌、肺癌、卵巢癌、结直肠癌、食管癌、胃癌、子宫癌、前列腺癌、胰腺癌和非霍奇金淋巴瘤(NHL)。研究采用了 Cox 比例危险分析法:总体而言,41.4%的患者在化疗开始至首个化疗疗程结束后三天内接受了G-CSF治疗。除了胰腺癌患者的使用率有所上升外,所有癌症的使用率都保持相对稳定。随着患者年龄的增长,G-CSF 的使用率也在下降。与最年轻的患者相比,年龄最大的患者接受 G-CSF 治疗的几率要低 43.0%(95% 置信区间:40.7-45.2%)。乳腺癌或 NHL 患者比其他癌症患者更有可能接受 G-CSF。女性、已婚、白人或西班牙裔、合并症较少的患者更有可能接受 G-CSF:讨论:G-CSF在罹患FN及相关并发症风险较高的人群中使用较少。提高对建议的依从性可以改善健康状况,尤其是对最年长的成年人、老年男性和黑人患者。
{"title":"Trends in the use of granulocyte colony stimulating factors for older patients with cancer, 2010 to 2019","authors":"Kaylee Fish ,&nbsp;Daoqi Gao ,&nbsp;Mukaila Raji ,&nbsp;Lodovico Balducci ,&nbsp;Yong-Fang Kuo","doi":"10.1016/j.jgo.2024.102049","DOIUrl":"10.1016/j.jgo.2024.102049","url":null,"abstract":"<div><h3>Introduction</h3><div>Older patients with cancer receiving myelosuppressive treatment are at an increased risk for developing febrile neutropenia (FN) or having chemotherapy dose-reductions or delays, resulting in suboptimal health outcomes. Granulocyte colony stimulating factors (G-CSF) are effective medications to reduce these adverse events and are recommended for patients <span><math><mo>≥</mo></math></span>65 years receiving chemotherapy with &gt;10 % FN risk. We sought to characterize the trends and predictors of G-CSF use between the youngest-old (66–74 years), middle-old (75–84 years), and oldest-old (<span><math><mo>≥</mo></math></span>85 years) patients with cancer.</div></div><div><h3>Materials and Methods</h3><div>We used registry data from SEER-Medicare for breast, lung, ovarian, colorectal, esophageal, gastric, uterine, prostate, pancreatic cancer, and non-Hodgkin lymphoma (NHL) diagnoses from 2010 to 2019. Cox proportional hazard analysis was used.</div></div><div><h3>Results</h3><div>Overall, 41.4 % of patients received G-CSF from chemotherapy initiation to three days after completion of the first chemotherapy course. The use rate remained relatively stable for all cancers, except for an increase in use for those with pancreatic cancer. G-CSF use decreased as patients got older. The oldest-old were 43.0 % (95 % confidence interval: 40.7–45.2 %) less likely to receive G-CSF compared to the youngest-old. Patients with breast cancer or NHL were more likely to receive G-CSF than those with other cancers. Patients who were female, married, White or Hispanic, and had fewer comorbidities were more likely to receive G-CSF.</div></div><div><h3>Discussion</h3><div>G-CSF is used less often in populations at higher risk of developing FN and related complications. Improving adherence to recommendations can improve health outcomes, especially in the oldest adults, older males, and Black patients.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"15 8","pages":"Article 102049"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142125941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive geriatric assessment as an indicator of postoperative recovery in older patients with colorectal cancer 老年综合评估作为老年结直肠癌患者术后恢复的指标。
IF 3 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.jgo.2024.101837
Fuminori Teraishi , Ryohei Shoji , Yoshitaka Kondo , Shunsuke Kagawa , Rie Tamura , Yoshikazu Matsuoka , Hiroshi Morimatsu , Toshiharu Mitsuhashi , Toshiyoshi Fujiwara
{"title":"Comprehensive geriatric assessment as an indicator of postoperative recovery in older patients with colorectal cancer","authors":"Fuminori Teraishi ,&nbsp;Ryohei Shoji ,&nbsp;Yoshitaka Kondo ,&nbsp;Shunsuke Kagawa ,&nbsp;Rie Tamura ,&nbsp;Yoshikazu Matsuoka ,&nbsp;Hiroshi Morimatsu ,&nbsp;Toshiharu Mitsuhashi ,&nbsp;Toshiyoshi Fujiwara","doi":"10.1016/j.jgo.2024.101837","DOIUrl":"10.1016/j.jgo.2024.101837","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"15 8","pages":"Article 101837"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141759171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hospital admissions in the last month of life for patients with advanced cancer residing in nursing homes 入住疗养院的晚期癌症患者在生命最后一个月的住院情况。
IF 3 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.jgo.2024.102048
Gabriela Spulber , Linda Björkhem-Bergman , Torbjörn Schultz , Peter Strang

Introduction

Overtreatment and frequent hospital admissions in patients at end-of-life has been shown in several studies, including in the nursing home (NH) setting. However, overtreatment in NH residents with advanced cancer has not been studied before. Our objective was to compare emergency room (ER) visits and hospital admissions in the last month of life and place of death among NH residents with or without advanced cancer.

Materials and Methods

This retrospective study is based on Region Stockholm's administrative database from 2015 to 2019. Demographic data, ER visits, and Hospital Frailty Risk Score (HFRS) were extracted for each subject. Univariable and multivariable analyses were performed, and odds ratios (OR) calculated.

Results

In total, 30,324 NH residents were identified, of which 1807 had advanced cancer. Advanced cancer was associated with more ER visits in the last month of life in the univariable analysis but not when adjusted for age, sex, and risk of frailty with an adjusted aOR of 1.07 (95 %CI 0.97–1.19). Having a cancer diagnosis was significantly associated with acute hospital admissions, although the association was rather weak with an aOR 1.13 (95 %CI 1.02–1.26). NH residents with advanced cancer were less likely to die in hospital than non-cancer residents: aOR 0.63 (95 %CI 0.54–0.73).

Discussion

NH residents with advanced cancer have a slightly higher risk of hospital admissions in the last month of life compared to non-cancer residents but are less likely to die in hospital. The probability of ER visits during the last month of life was similar between NH residents with and without cancer.
导言:多项研究显示,临终患者存在过度治疗和频繁入院的情况,包括在养老院(NH)环境中。然而,对于患有晚期癌症的疗养院居民的过度治疗,以前还没有过研究。我们的目的是比较患有或未患有晚期癌症的 NH 居民在生命最后一个月的急诊室就诊和入院情况以及死亡地点:这项回顾性研究基于斯德哥尔摩地区 2015 年至 2019 年的行政数据库。提取了每位受试者的人口统计学数据、急诊室就诊情况和医院虚弱风险评分(HFRS)。进行了单变量和多变量分析,并计算了几率比(OR):共发现了 30,324 名新罕布什尔州居民,其中 1807 人患有晚期癌症。在单变量分析中,晚期癌症与生命中最后一个月到急诊室就诊的次数较多有关,但在对年龄、性别和虚弱风险进行调整后,则与之无关,调整后的aOR为1.07(95 %CI 0.97-1.19)。癌症诊断与急性入院治疗有明显相关性,但相关性较弱,aOR 为 1.13(95 %CI 1.02-1.26)。与非癌症居民相比,患有晚期癌症的 NH 居民在医院死亡的可能性较低:aOR 为 0.63(95 %CI 为 0.54-0.73):讨论:与非癌症居民相比,患有晚期癌症的新罕布什尔州居民在生命最后一个月入院的风险略高,但死于医院的可能性较低。患有癌症和未患癌症的北卡罗来纳州居民在生命最后一个月到急诊室就诊的概率相似。
{"title":"Hospital admissions in the last month of life for patients with advanced cancer residing in nursing homes","authors":"Gabriela Spulber ,&nbsp;Linda Björkhem-Bergman ,&nbsp;Torbjörn Schultz ,&nbsp;Peter Strang","doi":"10.1016/j.jgo.2024.102048","DOIUrl":"10.1016/j.jgo.2024.102048","url":null,"abstract":"<div><h3>Introduction</h3><div>Overtreatment and frequent hospital admissions in patients at end-of-life has been shown in several studies, including in the nursing home (NH) setting. However, overtreatment in NH residents with advanced cancer has not been studied before. Our objective was to compare emergency room (ER) visits and hospital admissions in the last month of life and place of death among NH residents with or without advanced cancer.</div></div><div><h3>Materials and Methods</h3><div>This retrospective study is based on Region Stockholm's administrative database from 2015 to 2019. Demographic data, ER visits, and Hospital Frailty Risk Score (HFRS) were extracted for each subject. Univariable and multivariable analyses were performed, and odds ratios (OR) calculated.</div></div><div><h3>Results</h3><div>In total, 30,324 NH residents were identified, of which 1807 had advanced cancer. Advanced cancer was associated with more ER visits in the last month of life in the univariable analysis but not when adjusted for age, sex, and risk of frailty with an adjusted aOR of 1.07 (95 %CI 0.97–1.19). Having a cancer diagnosis was significantly associated with acute hospital admissions, although the association was rather weak with an aOR 1.13 (95 %CI 1.02–1.26). NH residents with advanced cancer were less likely to die in hospital than non-cancer residents: aOR 0.63 (95 %CI 0.54–0.73).</div></div><div><h3>Discussion</h3><div>NH residents with advanced cancer have a slightly higher risk of hospital admissions in the last month of life compared to non-cancer residents but are less likely to die in hospital. The probability of ER visits during the last month of life was similar between NH residents with and without cancer.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"15 8","pages":"Article 102048"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142108073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Support roles, carer burden, and decision-making preferences of carers of older adults with cancer 老年癌症患者照顾者的支持角色、照顾者负担和决策偏好。
IF 3 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.jgo.2024.102079
Wing Sze Lindsay Chan , Vasi Naganathan , Abby Fyfe , Alina Mahmood , Arnav Nanda , Anne Warby , Duong Pham , Natalie Southi , Sarah Sutherland , Erin Moth

Introduction

Older adults with cancer value the perspectives of significant others and their carers regarding decision-making about treatment. Understanding the support provided by carers, and their perspectives on involvement in treatment decision-making, can help us improve our communication with patients and their supports. We aimed to describe the roles, burden, and decision-making preferences of carers of older adults with cancer.

Materials and Methods

We performed a cross-sectional survey of carers of older adults (≥65y) with cancer at three centres in Sydney, Australia. Type, frequency, and perspectives on providing care were evaluated using Likert scales. Preferred and perceived role in treatment decision-making by modified Control Preferences Scale, and carer burden by Zarit Burden Index (ZBI-12), were evaluated. Preferred role in decision-making and carer burden were compared between groups (culturally and linguistically diverse backgrounds [CALD], sex, and carer age ≥ 65) by chi-squared or t-tests.

Results

One-hundred and fourteen returned surveys were included (23 partially completed). Carer characteristics: median age 55y (range 24–90), female (74 %), child (49 %) and spouse (35 %) of the care-recipient. Care-recipient characteristics: median age 75y (range 65–96), receiving anti-cancer treatment (85 %), and CALD background (44 %). Carers were frequently involved in communication and information gathering (45 % -80 %) and supported instrumental activities of daily living (IADLs) (43 % - 81 %) more frequently than basic activities of daily living (ADLs) (2–13 %). Most (91 %) preferred to be present when treatment options were discussed. Their preferred role in treatment decision-making was passive in 66 %, collaborative in 30 %, and active in 4 %, with most (72 %) playing their preferred role. The preferred role was associated with carer age (p = 0.01) and CALD background (p = 0.04), with younger (<65y) carers and those caring for CALD older adults preferring a more passive role. Carer burden was ‘low’ in 29 %, ‘moderate’ in 31 %, and ‘high’ in 39 %, and providing psychological support was rated most challenging.

Discussion

Carers of older adults with cancer play varied support roles, particularly in communication and information gathering. Carers prefer to be present for discussions about treatment options, though favour a passive role in treatment decision-making, upholding patient autonomy. Understanding the communication preferences of carers is an important consideration when supporting the patient in deciding treatment options and direction of care.
介绍:老年癌症患者非常重视重要他人及其照顾者对治疗决策的看法。了解照护者提供的支持以及他们对参与治疗决策的看法,有助于我们改善与患者及其支持者的沟通。我们旨在描述老年癌症患者照顾者的角色、负担和决策偏好:我们在澳大利亚悉尼的三个中心对癌症老年人(≥65 岁)的照顾者进行了横断面调查。采用李克特量表对护理类型、频率和提供护理的角度进行了评估。通过修改后的 "控制偏好量表"(Control Preferences Scale)评估了在治疗决策中的首选角色和感知角色,并通过扎里特负担指数(ZBI-12)评估了照护者的负担。通过卡方检验或 t 检验对不同组别(不同文化和语言背景 [CALD]、性别和照顾者年龄≥ 65 岁)在决策中的首选角色和照顾者负担进行比较:共收回 114 份调查问卷(23 份部分完成)。照顾者特征:中位数年龄 55 岁(24-90 岁不等),女性(74%),子女(49%)和配偶(35%)。护理对象特征:中位年龄 75 岁(65-96 岁不等),正在接受抗癌治疗(85%),有 CALD 背景(44%)。照护者经常参与沟通和信息收集(45 % - 80 %),支持工具性日常生活活动(IADLs)(43 % - 81 %)多于支持基本日常生活活动(ADLs)(2-13 %)。大多数患者(91%)希望在讨论治疗方案时在场。他们在治疗决策中的首选角色是被动型(66%)、合作型(30%)和主动型(4%),其中大多数人(72%)扮演自己首选的角色。首选角色与照顾者的年龄(p = 0.01)和 CALD 背景(p = 0.04)有关,年轻的照顾者(讨论:老年癌症患者的照护者扮演着不同的支持角色,尤其是在沟通和信息收集方面。照护者更愿意参与治疗方案的讨论,但在治疗决策中更倾向于扮演被动的角色,以维护患者的自主权。在支持患者决定治疗方案和护理方向时,了解照护者的沟通偏好是一个重要的考虑因素。
{"title":"Support roles, carer burden, and decision-making preferences of carers of older adults with cancer","authors":"Wing Sze Lindsay Chan ,&nbsp;Vasi Naganathan ,&nbsp;Abby Fyfe ,&nbsp;Alina Mahmood ,&nbsp;Arnav Nanda ,&nbsp;Anne Warby ,&nbsp;Duong Pham ,&nbsp;Natalie Southi ,&nbsp;Sarah Sutherland ,&nbsp;Erin Moth","doi":"10.1016/j.jgo.2024.102079","DOIUrl":"10.1016/j.jgo.2024.102079","url":null,"abstract":"<div><h3>Introduction</h3><div>Older adults with cancer value the perspectives of significant others and their carers regarding decision-making about treatment. Understanding the support provided by carers, and their perspectives on involvement in treatment decision-making, can help us improve our communication with patients and their supports. We aimed to describe the roles, burden, and decision-making preferences of carers of older adults with cancer.</div></div><div><h3>Materials and Methods</h3><div>We performed a cross-sectional survey of carers of older adults (≥65y) with cancer at three centres in Sydney, Australia. Type, frequency, and perspectives on providing care were evaluated using Likert scales. Preferred and perceived role in treatment decision-making by modified Control Preferences Scale, and carer burden by Zarit Burden Index (ZBI-12), were evaluated. Preferred role in decision-making and carer burden were compared between groups (culturally and linguistically diverse backgrounds [CALD], sex, and carer age ≥ 65) by chi-squared or <em>t</em>-tests.</div></div><div><h3>Results</h3><div>One-hundred and fourteen returned surveys were included (23 partially completed). Carer characteristics: median age 55y (range 24–90), female (74 %), child (49 %) and spouse (35 %) of the care-recipient. Care-recipient characteristics: median age 75y (range 65–96), receiving anti-cancer treatment (85 %), and CALD background (44 %). Carers were frequently involved in communication and information gathering (45 % -80 %) and supported instrumental activities of daily living (IADLs) (43 % - 81 %) more frequently than basic activities of daily living (ADLs) (2–13 %). Most (91 %) preferred to be present when treatment options were discussed. Their preferred role in treatment decision-making was passive in 66 %, collaborative in 30 %, and active in 4 %, with most (72 %) playing their preferred role. The preferred role was associated with carer age (<em>p</em> = 0.01) and CALD background (<em>p</em> = 0.04), with younger (&lt;65y) carers and those caring for CALD older adults preferring a more passive role. Carer burden was ‘low’ in 29 %, ‘moderate’ in 31 %, and ‘high’ in 39 %, and providing psychological support was rated most challenging.</div></div><div><h3>Discussion</h3><div>Carers of older adults with cancer play varied support roles, particularly in communication and information gathering. Carers prefer to be present for discussions about treatment options, though favour a passive role in treatment decision-making, upholding patient autonomy. Understanding the communication preferences of carers is an important consideration when supporting the patient in deciding treatment options and direction of care.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"15 8","pages":"Article 102079"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142467439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Providing early access to geriatric oncology services in a regional cancer centre - A two-year experience in the establishment of a Geriatric Oncology Nurse Navigator Model. 在地区癌症中心提供早期老年肿瘤学服务--建立老年肿瘤学护士导航模式的两年经验。
IF 3 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2024-10-31 DOI: 10.1016/j.jgo.2024.102145
Sebastian Kang, Sally Allen, Amy Brown, Dinuka Ariyarathna, Sabe Sabesan, Corinne Ryan, Suresh Varma, Zulfiquer Otty, Abhishek Joshi, Shivanshan Pathmanathan

Introduction: Older patients with cancer often face increased risks of adverse reactions and complications when undergoing systemic therapy. In 2020, the Townsville Cancer Centre in North Queensland established a nurse navigator led geriatric oncology service for patients aged 75 years and above referred for systemic therapy for solid organ malignancy. This study sought to evaluate the safety outcomes and trends in the administration of systemic therapy in older patients following the introduction of this service.

Materials and methods: A retrospective study was conducted at a single centre, focusing on patients aged 75 years and above referred for chemotherapy or immunotherapy for solid organ malignancies. Patients referred after the implementation of the service were classified as the geriatric assessment cohort, while those referred before were categorized as the historical cohort. Outcome measures included unplanned hospital admissions, duration of hospital stays, rates of systemic therapy de-escalation, and frailty identified during geriatric assessments.

Results: The study included 129 patients, with 60 in the geriatric assessment cohort and 69 in the historical cohort. The geriatric assessment cohort exhibited a significant decrease in both the average number of hospital admissions per patient compared to the historical cohort (0.59 vs. 1.13, p = 0.01) and the average length of hospital stay (4.3 days vs. 6.7 days, p = 0.04). Rates of systemic therapy de-escalation were comparable between the two cohorts (47 % vs. 59 %, p = 0.16). Frailty was frequently identified during geriatric assessments, requiring intervention both before and during treatment.

Discussion: Our two-year observation of the nurse navigator-led geriatric oncology model suggests that it contributed to improved safety outcomes, leading to reductions in unplanned hospitalizations and lengths of hospital stays, without significant changes in the rates of de-escalated systemic therapy.

简介老年癌症患者在接受系统治疗时,往往会面临更高的不良反应和并发症风险。2020年,北昆士兰州汤斯维尔癌症中心(Townsville Cancer Centre)为75岁及以上转诊接受全身治疗的实体器官恶性肿瘤患者设立了由护士导航员领导的老年肿瘤学服务。本研究旨在评估引入该服务后老年患者接受系统治疗的安全结果和趋势:在一家中心开展了一项回顾性研究,主要针对因实体器官恶性肿瘤转诊接受化疗或免疫疗法的 75 岁及以上患者。实施该服务后转诊的患者被归类为老年评估队列,而之前转诊的患者被归类为历史队列。结果指标包括非计划入院率、住院时间、系统疗法降级率以及老年病评估中发现的虚弱情况:研究共纳入了 129 名患者,其中 60 人属于老年评估队列,69 人属于历史队列。与历史队列相比,老年医学评估队列中每位患者的平均入院次数(0.59 对 1.13,p = 0.01)和平均住院时间(4.3 天对 6.7 天,p = 0.04)均显著减少。两组患者放弃系统治疗的比例相当(47% 对 59%,p = 0.16)。在老年病评估过程中经常发现体弱现象,需要在治疗前和治疗过程中进行干预:讨论:我们对以护士导航员为主导的老年肿瘤治疗模式进行了为期两年的观察,结果表明,该模式有助于改善安全结果,从而减少了非计划住院和住院时间,但系统治疗的降级率并未发生显著变化。
{"title":"Providing early access to geriatric oncology services in a regional cancer centre - A two-year experience in the establishment of a Geriatric Oncology Nurse Navigator Model.","authors":"Sebastian Kang, Sally Allen, Amy Brown, Dinuka Ariyarathna, Sabe Sabesan, Corinne Ryan, Suresh Varma, Zulfiquer Otty, Abhishek Joshi, Shivanshan Pathmanathan","doi":"10.1016/j.jgo.2024.102145","DOIUrl":"https://doi.org/10.1016/j.jgo.2024.102145","url":null,"abstract":"<p><strong>Introduction: </strong>Older patients with cancer often face increased risks of adverse reactions and complications when undergoing systemic therapy. In 2020, the Townsville Cancer Centre in North Queensland established a nurse navigator led geriatric oncology service for patients aged 75 years and above referred for systemic therapy for solid organ malignancy. This study sought to evaluate the safety outcomes and trends in the administration of systemic therapy in older patients following the introduction of this service.</p><p><strong>Materials and methods: </strong>A retrospective study was conducted at a single centre, focusing on patients aged 75 years and above referred for chemotherapy or immunotherapy for solid organ malignancies. Patients referred after the implementation of the service were classified as the geriatric assessment cohort, while those referred before were categorized as the historical cohort. Outcome measures included unplanned hospital admissions, duration of hospital stays, rates of systemic therapy de-escalation, and frailty identified during geriatric assessments.</p><p><strong>Results: </strong>The study included 129 patients, with 60 in the geriatric assessment cohort and 69 in the historical cohort. The geriatric assessment cohort exhibited a significant decrease in both the average number of hospital admissions per patient compared to the historical cohort (0.59 vs. 1.13, p = 0.01) and the average length of hospital stay (4.3 days vs. 6.7 days, p = 0.04). Rates of systemic therapy de-escalation were comparable between the two cohorts (47 % vs. 59 %, p = 0.16). Frailty was frequently identified during geriatric assessments, requiring intervention both before and during treatment.</p><p><strong>Discussion: </strong>Our two-year observation of the nurse navigator-led geriatric oncology model suggests that it contributed to improved safety outcomes, leading to reductions in unplanned hospitalizations and lengths of hospital stays, without significant changes in the rates of de-escalated systemic therapy.</p>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":" ","pages":"102145"},"PeriodicalIF":3.0,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of geriatric oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1